VLO
30
-3
HD
44
-5
RIG
38
-3
UNP
46
-2
HCP
58
2
XEL
50
-7
CAT
61
-3
WMT
59
-3
EMR
50
2
AAL
50
2
CNP
47
-2
FLS
69
2
ORLY
60
-4
L
55
-4
KLAC
45
3
HES
56
-2
AMZN
57
2
JWN
60
3
TRIP
73
4
CRM
62
3
VLO
30
-3
HD
44
-5
RIG
38
-3
UNP
46
-2
HCP
58
2
XEL
50
-7
CAT
61
-3
WMT
59
-3
EMR
50
2
AAL
50
2
CNP
47
-2
FLS
69
2
ORLY
60
-4
L
55
-4
KLAC
45
3
HES
56
-2
AMZN
57
2
JWN
60
3
TRIP
73
4
CRM
62
3
Financhill
Back

Sarepta Therapeutics 10K Form

Sell
38

SRPT
Sarepta Therapeutics

Last Price:
128.96
Seasonality Move:
11.13%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SRPT News And Ratings

See the #1 stock for the next 7 days that we like better than SRPT

SRPT Financial Statistics

Sales & Book Value

Annual Sales: $1.24B
Cash Flow: $-14.23M
Price / Cash Flow: 0
Annual Sales: $11.30
Price / Book: 11.53

Profitability

EPS (TTM): 0.74000
Net Income (TTM): $47.3M
Gross Margin: $1.09B
Return on Equity: 5.37%
Return on Assets: 1.46%

Sarepta Therapeutics Earnings Forecast

Key Sarepta Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 28 years for SRPT is 87.91%.
  • The Selling, General & Administrative Expenses for SRPT have been equal to 38.76% of Gross Profit Margin.
  • The Research & Development expenses have been 70.57% of Revenue.
  • The Interest Expense is -4.11% of Operating Income.
  • The Net Earning history of SRPT is -43.11% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 14 years.

Sarepta Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SRPT
CUSIP: 803607
Website: sarepta.com

Debt

Debt-to-Equity Ratio: 1.14
Current Ratio: 3.9
Quick Ratio: 2.69

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 10.9

SRPT Technical Analysis vs Fundamental Analysis

Sell
38
Sarepta Therapeutics (SRPT) is a Sell

Is Sarepta Therapeutics a Buy or a Sell?